The Mission of the Clinical Research Center (CRC) is to promote clinical and translational research in order to provide advance care that is currently unavailable for the residents of our Tristate Metro Community (West Virginia, Southern Ohio and Eastern Kentucky). All of our clinical trials adhere to both our vision as well as the guiding principles (below). We encourage all residents of the Tristate community to visit the website periodically to discover if any clinical trials may be of interest to them or their family.
The CRC has been organized as a centralized unit within the Office of Research and Graduate Education at Joan C. Edwards School of Medicine (JCESOM). The centralized CRC better coordinates and promotes all clinical research at JCESOM. The primary office consists of the Vice Dean for Research and Graduate Education, Medical Director of the CRC, Director of Clinical Informatics and support staff (all listed below). The CRC is located in the Charles H. McKown Translational Genomic Research Institute at Marshall University Medical Center in Cabell Huntington Hospital.
We will be a world leader in community academic clinical research supporting medical innovation and care in Appalachia. To realize this vision, we will strive to:
Below is a list of currently enrolling Clinical Trials at the Appalachian Clinical and Translational Science Institute (ACTSI). If you would like additional information about a specific trial, you can call the contact number provided and speak with a study coordinator.
Additional information about each trial can be obtained at ClinicalTrials.gov by clicking on the descriptions below
|Study ID||PI||Description||Contact Information|
|NCT02329327||Cornell||"A Study in Patients with Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Revers the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (ANNEXA-4)"||Robin Ashford: 304-691-1082|
|NCT01442194||Ferguson||"Long-term, Prosepctive, Multi- national, parallel-cohort study Monitoring Safety in Patients with MS Newly Started with Fingolimod Once Daily or Treated with Another Approved Disease- Modifying Therapy" CLR1104||Linda Morgan: 304-691-1213|
|NCT02239120||Nolte||"Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)"||Melissa Marcum: 304-691-8560
Rebecca Smith: 304-691-1834
|NCT02477618||Shah||"A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of SAGE547 Injection in the Treatment of Subjects with Super Refrac-tory Status Epilepticus"||Robin Ashford: 304-691-1082
Doug Melton: 304-691-8618
|NCT01797185||Ferguson||"Open-label, safety study of SPARC1104 in Subjects with Spasticity due to MS"||Linda Morgan: 304-691-1213|
|NCT02373904||Cheung||"A Prospective, Multi-Center Study of the IlluminOSS Photodynamic Bone Sta-bilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus from Metastatic Bone Disease"||Linda Morgan: 304-691-1213|
|NCT03114657||Neitch||"A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease"||Melissa Marcum: 304-691-8560|
|NCT02792218||Ferguson||"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Ofatumumab versus Teriflunomide in Patients with Relapsing Multiple Sclerosis"||Linda Morgan: 304-691-1213
Doug Melton: 304-691-8618
|NCT02878330||Lambros||"A Phase 2B Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Mono-clonal Antibody with an Extended Half-Life Against Respiratory Synctial Virus, in Healthy Preterm Infants"||Robin Ashford: 304-691-1082|